S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

被引：0
|
作者：
Patel, Sapna Pradyuman
Othus, Megan
Moon, James
Tetzlaff, Michael T.
Buchbinder, Elizabeth Iannotti
Sondak, Vernon K.
Lowe, Michael C.
Campos, Danae
Sharon, Elad
Korde, Larissa A.
Carson, William Edgar
Ribas, Antoni
Grossmann, Kenneth F.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Southwest Oncol Grp, Stat Ctr, Seattle, WA USA
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Emory Univ, Dept Surg, Atlanta, GA USA
[7] SWOG Operatons Off, San Antonio, TX USA
[8] NCI, Bethesda, MD 20892 USA
[9] NCI, Clin Invest Branch, Bethesda, MD 20892 USA
[10] Ohio State Univ, Dept Surg, Comprehens Canc Ctr, Columbus, OH 43210 USA
[11] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS10090
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer—The Randomized Multicenter Phase II NEPAFOX Trial
    Thorsten O. Goetze
    Alexander Reichart
    Ulli S. Bankstahl
    Claudia Pauligk
    Maria Loose
    Thomas W. Kraus
    Moustafa Elshafei
    Wolf O. Bechstein
    Jörg Trojan
    Matthias Behrend
    Nils Homann
    Marino Venerito
    Wolfram Bohle
    Michael Varvenne
    Claus Bolling
    Dirk M. Behringer
    Karsten Kratz-Albers
    Gabriele M. Siegler
    Wael Hozaeel
    Salah-Eddin Al-Batran
    Annals of Surgical Oncology, 2024, 31 : 4121 - 4122
  • [22] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Hozaeel, Wael
    Pauligk, Claudia
    Homann, Nils
    Luley, Kim
    Kraus, Thomas Werner
    Trojan, Jorg
    Bechstein, Wolf O.
    Grimm, Kersten
    Heise, Bettina
    Schmiegel, Wolff
    Pink, Daniel
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Al-Batran, Salah-Eddin
    Reichart, Alexander
    Bankstahl, Ulli Simone
    Pauligk, Claudia
    Kraus, Thomas Werner
    Bechstein, Wolf Otto
    Trojan, Jorg
    Behrend, Matthias
    Potenberg, Jochem
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Alber, Karsten
    Siegler, Gabriele Margareta
    Hozaeel, Wael
    Goetze, Thorsten Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [24] Phase II trial of carboplatin, paclitaxel and temozolomide in metastatic melanoma.
    Araujo-Mino, Emilio Paul
    Shaheen, Montaser F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] A phase Ill randomized trial comparing FDA approved standard of care adjuvant therapy to one year of pembrolizumab in patients with high risk resected melanoma. SWOG 1404
    Grossmann, Kenneth F.
    Sondak, Vernon K.
    Othus, Megan
    Tarhini, Ahmad
    Patel, Sapna
    Kirkwood, John M.
    Ribas, Antoni
    Moon, James
    CANCER RESEARCH, 2016, 76
  • [26] A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.
    Sato, Takami
    Orloff, Marlana M.
    Valsecchi, Matias Emanuel
    Shimada, Ayako
    Chervoneva, Inna
    Sharpe-Mills, Erin
    Klose, Haley
    Norcini, Jessica
    Belinsky, Jill
    Sato, Shingo
    Hulse, Liam
    Shields, Carol L.
    Shields, Jerry A.
    Mastrangelo, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] NEOplus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma
    Mao, L.
    Bai, X.
    Wei, X.
    Dai, J.
    Cui, C-L.
    Chi, Z.
    Sheng, X.
    Lian, B.
    Wang, X.
    Bixia, T.
    Si, L.
    Guo, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S951 - S951
  • [28] Phase II trial of neoadjuvant temozolomide in advanced melanoma
    Shah, G. D.
    Coit, D. G.
    Brady, M.
    Wolchok, J. D.
    Carvajal, R. D.
    Busam, K.
    Panageas, K.
    Roman, R.
    Viale, A.
    Socci, N.
    Chapman, P. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial
    Goetze, Thorsten O.
    Reichart, Alexander
    Bankstahl, Ulli S.
    Pauligk, Claudia
    Loose, Maria
    Kraus, Thomas W.
    Elshafei, Moustafa
    Bechstein, Wolf O.
    Trojan, Joerg
    Behrend, Matthias
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Albers, Karsten
    Siegler, Gabriele M.
    Hozaeel, Wael
    Al-Batran, Salah-Eddin
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (6) : 4121 - 4122
  • [30] SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.
    Mowery, Yvonne Marie
    Ballman, Karla V.
    Riedel, Richard F.
    Brigman, Brian E.
    Attia, Steven
    Meyer, Christian Frederick
    Schuetze, Scott
    Burgess, Melissa Amber
    Chmielowski, Bartosz
    Dickson, Mark Andrew
    Hartner, Lee P.
    Milhem, Mohammed M.
    Tinoco, Gabriel
    Van Tine, Brian Andrew
    Wagner, Andrew J.
    Reinke, Denise K.
    Kirsch, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345